Tonghua Dongbao launches employee stock plan for R&D and production staff

Tonghua Dongbao Pharmaceutical Co., Ltd. has established an employee stock ownership plan for its research, development, and production system's core personnel, totaling no more than 122 individuals. The plan aims to raise up to 30.73 million yuan and will acquire up to 7 million shares of the company's repurchased A-shares, representing approximately 0.357% of the current total share capital. The acquisition price is set at 4.39 yuan per share.

The plan has a 60-month duration, with an initial lock-up period of 12 months for the first grant, followed by two subsequent unlocking periods at 24 and 36 months, respectively, each with specific unlocking percentages (40%, 30%, 30%). Performance-based unlocking conditions are tied to annual company-level R&D and production milestones for 2026-2028, including NDA submissions, approvals, IND submissions, and overseas registration approvals, alongside individual performance assessments.

An estimated expense of 28.028 million yuan will be recognized over the 2025-2028 period. This initiative is designed to align employee and shareholder interests, enhance employee cohesion, and bolster the company's competitiveness and sustainable development.